Mindera Health™ Signs Network Provider Agreement with MultiPlan
16. Dezember 2024 08:00 ET
|
Mindera Health
Vista, CA, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a leader in precision medicine for dermatological conditions, today announced their participation in MultiPlan’s national PPO networks....
Mindera Health™ Welcomes New Vice President of Sales
05. Dezember 2024 08:00 ET
|
Mindera Health
Vista, CA, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Mindera Health, a pioneer in precision medicine combining machine learning with Next-Generation Sequencing to create Dermal Intelligence™, announces the...
Plaque Psoriasis Research Report 2024: 7 Major Market and 61 Additional Country Market Analysis and Sales Forecasts 2020-2030
18. November 2024 10:55 ET
|
Research and Markets
Dublin, Nov. 18, 2024 (GLOBE NEWSWIRE) -- The "Plaque Psoriasis: 68-Market Analysis and Sales Forecast" report has been added to ResearchAndMarkets.com's offering.The analyst estimates that sales...
Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements
13. November 2024 16:05 ET
|
Alumis Inc.
Alumis reports third quarter 2024 financial results, highlights positive data and near term milestones for its ongoing clinical programs.
Dermatology Collaboration and Licensing Agreements Analysis Report 2024: Detailed Review and Access to Contract Documents - Upfront, Milestone, Royalties, Company A-Z, Therapy and Technology
11. November 2024 04:47 ET
|
Research and Markets
Dublin, Nov. 11, 2024 (GLOBE NEWSWIRE) -- The "Dermatology Collaboration and Licensing Deals 2016-2024" report has been added to ResearchAndMarkets.com's offering.Fully revised and updated, the...
Understanding the United States Psoriasis Patient Experience to Make Informed Business Decisions, Identify Opportunities, and Understand Potential Challenges
25. Oktober 2024 04:05 ET
|
Research and Markets
Dublin, Oct. 25, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: Understanding the Psoriasis Patient Experience" report has been added to ResearchAndMarkets.com's offering. This...
Tumor Necrosis Factor Inhibitor Drugs Market to hit USD 50 billion by 2032, says Global Market Insights Inc.
02. Oktober 2024 05:42 ET
|
Global Market Insights Inc.
Selbyville, Delaware, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Tumor Necrosis Factor Inhibitor Drugs Market size valued at USD 41.3 billion in 2023 and is projected to grow at a CAGR of 2.2% from...
Late-Breaking Data at EADV of ESK-001, an Oral TYK2 Inhibitor for the Treatment of Psoriasis, Demonstrate Significant Responses with Sustained Increases Over 28 Weeks in Phase 2 OLE Study
27. September 2024 09:00 ET
|
Alumis Inc.
Late breaking research presentation at EADV shows increasing and sustained responses in 28-week Phase 2 data for ESK-001 in psoriasis
U.S. Psoriasis Treatment Awareness & Satisfaction Report: A Review of 2023 - Provides Valuable Insights Into Must-Have Patient-Reported Data Points
26. September 2024 04:17 ET
|
Research and Markets
Dublin, Sept. 26, 2024 (GLOBE NEWSWIRE) -- The "Psoriasis in the United States: A Review of 2023 - Key Insights into Treatment Awareness & Satisfaction" report has been added to ...
Mindera Health™ becomes a Medi-Cal™ Credentialled Provider
19. August 2024 08:00 ET
|
Mindera Health
San Diego, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Mindera Health, developer of Mind.Px™, the first realization of precision medicine in psoriasis, has completed the credentialling process to become a...